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Abstract
Background: Shiga toxins (Stxs) are the major agents responsible for hemorrhagic colitis and hemolytic-
uremic syndrome (HUS) during infections caused by Stx-producing Escherichia coli (STEC) such as serotype
O157:H7. Central nervous system (CNS) involvement is an important determinant of mortality in diarrhea
associated-HUS. It has been suggested that vascular endothelial injuries caused by Stxs play a crucial role
in the development of the disease. The current study investigates the relationship between the cytotoxic
effects of Stxs and inflammatory responses in a rabbit brain treated with Stx2.
Methods: In a rabbit model treated with purified Stx2 or PBS(-), we examined the expression of the Stx
receptor globotriaosylceramide (Gb3)/CD77 in the CNS and microglial activation using
immunohistochemistry. The relationship between inflammatory responses and neuronal cell death was
analyzed by the following methods: real time quantitative reverse transcriptase (RT)-polymerase chain
reaction (PCR) to determine the expression levels of pro-inflammatory cytokines, and the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) method to detect
apoptotic changes.
Results: Gb3/CD77 expression was detected in endothelial cells but not in neurons or glial cells. In the
spinal cord gray matter, significant levels of Gb3/CD77 expression were observed. Severe endothelial
injury and microvascular thrombosis resulted in extensive necrotic infarction, which led to acute neuronal
damage. Conversely, in the brain, Stx receptor expression was much lower. The observed neuropathology
was less severe. However, neuronal apoptosis was observed at the onset of neurological symptoms, and
the number of apoptotic cells significantly increased in the brain at a later stage, several days after onset.
Microglial activation was observed, and tumor necrosis factor (TNF)-α and interleukin (IL)-1β mRNA in
the CNS parenchyma was significantly up-regulated. There was significant overexpression of TNF-α
transcripts in the brain.
Conclusion: This study indicates that Stx2 may not directly damage neural cells, but rather inflammatory
responses occur in the brain parenchyma in response to primary injury by Stx2 in vascular endothelial cells
expressing Gb3/CD77. These findings suggest that neuroinflammation may play a critical role in
neurodegenerative processes during STEC infection and that anti-inflammatory intervention may have
therapeutic potential.
Published: 21 March 2008
Journal of Neuroinflammation 2008, 5:11 doi:10.1186/1742-2094-5-11
Received: 4 February 2008
Accepted: 21 March 2008
This article is available from: http://www.jneuroinflammation.com/content/5/1/11
© 2008 Takahashi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
Page 2 of 12
(page number not for citation purposes)
Background
Shiga toxin (Stx)-producing Escherichia coli (STEC), such
as serotype O157:H7, produces 1 or both of the 2 antigen-
ically distinct toxins Stx1 and Stx2 [1]. These toxins in the
circulation of patients infected with STEC are the major
cause of hemorrhagic colitis and the hemolytic-uremic
syndrome (HUS) associated with the prodrome of
diarrhea [2]. The extent and severity of extrarenal involve-
ment, particularly the neurological impairment, are
important determinants in the poor prognosis of STEC-
associated HUS patients [3]. Pathological examination
has shown that endothelial injury of small vessels and
microvascular thrombosis are the prominent changes
occurring in multiple organs, including the CNS [2,3].
Animal models treated with Stx1 [4,5] or Stx2 [6], also
develop neurological symptoms and exhibit similar neu-
ropathology. Stx1- or Stx2-binding was immunohisto-
chemically demonstrated in small vessels and/or the
subsets of some cells in the lesions, but not in the neurons
[4,7].
Stx1 and Stx2 are AB5 holotoxins that consist of an enzy-
matic A subunit and 5 copies of a binding B subunit [8].
The B subunits specifically bind to the terminal [Galα
(1–4)Gal] disaccharides of the receptor Gb3/CD77 con-
sisting of a trisaccharide β-linked ceramide (globotriaosyl-
ceramide) that is expressed on the cell membrane [9,10].
Stxs are then internalized with Gb3/CD77 and retro-
gradely transported from the endosomes through the
trans-golgi network and golgi apparatus to the endoplas-
mic reticulum [9]. The A subunit of the toxin is then
cleaved and translocated into the cytosol; it then inhibits
host cell protein synthesis by RNA N-glucosidase activity,
resulting in cell death [10]. Recent studies have reported
that cell death occurs by apoptosis [11,12]. Toxin-binding
to Gb3/CD77 is the primary determinant of the cytotoxic
and pathological effects of Stxs. However, Gb3/CD77
expression in the CNS parenchyma has not been well
examined, except in the dorsal root ganglia (DRG) [13].
Furthermore, the direct cytotoxic actions of Stxs against
neurons and glial cells remain unclear.
CNS responses to a variety of insults incorporate a wide
spectrum of cellular responses that include microglial acti-
vation [14,15] and local production of endogenous mol-
ecules such as pro-inflammatory cytokines, reactive
oxygen, and nitrogen species that affect neuronal integrity
[reviewed in [16] and [17]]. These inflammatory
responses in the CNS are now recognized to play a critical
role in the pathogenesis and progression of acute and
chronic neurodegenerative diseases, including stroke [18],
Alzheimer's disease [19,20], Parkinson's disease [21], and
viral infection [22,23]. It has been demonstrated that pro-
inflammatory cytokines, particularly TNF-α, induce neu-
ronal apoptosis in human brain cell cultures and animal
models through TNF/TNF receptor signaling [24,25] and
further production of other inflammatory and/or neuro-
toxic molecules [19,21]. Administration of TNF-α to mice
infected with Escherichia coli O157:H7 modified the neu-
rological signs and pathology [26]. In the case of neuro-
logical impairment during STEC infection, however, little
is known about the relationship between inflammatory
responses in the CNS due to the toxin and the neurode-
generative events in either patients or animal models.
In the current study, we showed the regional distribution
and cellular localization of Gb3/CD77 expression in the
CNS parenchyma of a rabbit model in order to examine
whether the toxins are able to directly injure neuronal
cells. Further, we investigated the relationship between
neuropathology and the interaction of toxin with Gb3/
CD77 and that between inflammatory processes in the
CNS and neuronal cell death in rabbits treated with Stx2.
Materials and methods
Toxin and animals
The Stx2 preparation was kindly provided as described
previously [27] by Denka Seiken Co., Ltd., (Niigata,
Japan). The same lot of toxin was used for all experiments
in this study. The protein content of the toxin was 130 μg/
ml as determined by Bradford method. The endotoxin
content was 34.5 pg/ml as measured by a limulus test (ES-
Test Wako Kit), using computerized turbidimetric equip-
ment (Wako Chemical Industries, Co. Ltd, Osaka, Japan)
[28]. Biological activity of Stx2 assessed by cytotoxicity on
Vero cells was found to be 5 × 106 CD50/μg protein.
Japanese male white rabbits (Japan SLC, Inc., Hama-
matsu, Japan) weighing 2.2 to 2.4 kg were used through-
out the experiments. All protocols used in this study were
in accordance with the Guidelines for Animal Experi-
ments of Iwate Medical University. Animals were accli-
mated to standard laboratory conditions with free access
to rabbit chow and water. In each experiment, at least 2
rabbits per group were used. The toxin was injected into
the left marginal ear vein in a single bolus. Six doses of 0.1
to 4.0 μg/kg body weight of Stx2 were administered for
clinical evaluation. For other experiments, including his-
topathological examination and gene expression, 2.5 μg/
kg of toxin were administered by the same route. Controls
were untreated rabbits injected with PBS(-) as above.
Laboratory tests
Blood samples were collected before administration of
Stx2 and at the onset of paralysis. Hematology, blood urea
nitrogen, creatinine, alanine aminotransferase, aspartate
aminotransferase, and amylase were measured by stand-
ard laboratory procedures in our hospital. The presence of
blood in stools was tested using the Occult Blood Slide 5
Kit (Shionogi & Co., Ltd., Osaka, Japan).Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
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Tissue preparation
Animals were intravenously injected with a lethal dose of
pentobarbital sodium and then rapidly perfused with ster-
ile physiological saline transcardially, followed by 2%
paraformaldehyde (PFA). Brain that denote the cerebrum,
midbrain, cerebellum and brain stem, spinal cord with
root ganglia and nerve fibers were removed and post-fixed
with 4% PFA overnight at 4°C. The tissue was paraffin-
embedded and sliced at 5 μm for histopathology, immu-
nohistochemistry, and the terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end-labeling
(TUNEL) assay. For the immunofluorescence assay (IFA)
tissue blocks were freshly embedded and frozen after cryo-
protection as described previously [29]. Tissue blocks
were stored at -70°C until sectioning.
Immunohistochemistry
Localization of Gb3/CD77 was examined by IFA. Cryosec-
tions cut at 7 μm were fixed with 4% PFA for 10 min
immediately prior to IFA and incubated with anti-human
CD77 rat IgM antibody [13] (1:100 dilution, Beckman
Coulter, Inc., Fullerton, CA) or with rat IgM isotype as a
negative control (1:100 dilution, Beckman Coulter) for
24~96 hrs at 4°C, followed by reaction with anti-rat IgM
goat IgG F(ab)2 antibody-FITC conjugate (1:200 dilution,
Beckman Coulter) for 30 min at room temperature. To
examine the cellular localization of Gb3/CD77, double-
staining with rhodamine conjugated Ricinus communis
agglutinin I (RCA 120) (1:5,000 dilution, Vector Labora-
tories, Inc., Burlingame, CA) was carried out overnight at
4°C on the same sections after Gb3/CD77 detection. The
sections were observed with the LSM 510 confocal laser
scanning microscopy (Carl Zeiss, Oberkochen, Germany).
Paraffin-embedded sections were stained for microglial
cells as described previously [23,30], with some modifica-
tion. Briefly, deparaffinized sections were pretreated with
3% H2O2 for 10 min to quench the endogenous peroxi-
dase activity, and were then incubated with biotinylated
RCA 120 (1:3,000 dilution) or Griffonia simplicifolia lectin
I-B4 isolectin (GSL I-B4) (1:2,000 dilution, Vector) over-
night at 4°C. This was followed by a reaction with perox-
idase conjugated streptavidin (DAKO). The color reaction
was performed using 0.5 mg/ml of diaminobenzidine
(DAB) (Sigma-Aldrich, Inc., St. Louis, MO) substrate solu-
tion with 0.02 % of H2O2. Sections were counterstained
with methyl green and mounted.
TUNEL assay
In order to detect in situ DNA fragmentation, the TUNEL
assay was performed using the In situ Apoptosis Detection
Kit (Takara Bio Inc., Otsu, Japan) according to the manu-
facturer's protocols. Briefly, deparaffinized sections were
permeabilized with proteinase K (DAKO) and treated
with 3% H2O2 as above. Sections were incubated with
Labeling Safe Buffer, i.e, an end-labeling mixture contain-
ing FITC-conjugated dUTP and TdT Enzyme, at 37°C for
60 min. Tissue sections were reacted with anti-FITC horse-
radish peroxidase-conjugated antibody for 30 min at
37°C. Color reaction with DAB was performed, followed
by counterstaining with methyl green as above. TUNEL
assay controls included omission of TdT and sections
from rabbits (n = 2) treated with PBS (-). To estimate
apoptotic cell death quantitatively, tissue sections of rab-
bits treated with 2.5 μg/kg of Stx2 were examined at the
onset and at a later stage several days after onset (n = 2 in
each group). Apoptotic cells in 16 to 50 fields and TUNEL-
positive vessels in 140 to 160 fields were counted at 100×
magnification in 3 sections from each region of the brain
parenchyma.
Real-time quantitative reverse transcription-polymerase 
chain reaction
Total RNA was extracted from 12 regions of the CNS using
NucleoSpin RNA II (Macherey-Nagel GmbH & Co. KG,
Düren, Germany) and 1 μg of total RNA was used for
cDNA synthesis with oligo dT and MMLV-RT (Invitrogen
Corp., Carlsbad, CA). Two μl of each cDNA product was
subjected to TNF-α and IL-1β mRNA quantitation using
SYBR Green PCR Master Mix [31] and an ABI PRISM 7700
Sequence Detection System (SDS) (Applied Biosystems,
Foster City, CA), followed by a dissociation curve analysis
and subsequent agarose gel electrophoresis to confirm
amplification specificity. The following primer sets were
used: TNF-α (size, 243 bp; melting temperature (Tm),
87.5°C), forward [32]: 5'-AGCCCACGTAGTAG-
CAAACCC-3', reverse: 5'-GAGAGGAGGTTGACCTTGTT-
3' [GenBank: M12485 and M12486]; IL-1β (size, 264 bp;
Tm, 81.0°C), forward [33]: 5'-GAATCTGAAC-
CAACAAGTGG-3', reverse: 5'-ATGTACCAGTT-
GGGGAACT-3' [GenBank: M26295]; and GAPDH was
used as an endogenous reference (size, 308 bp; Tm,
88.3°C), forward: 5'-TCTCTCAAGATTGTCAGCAA-3',
reverse: 5'-AGGTCCACGACCGACACGTT-3' [GenBank:
L23961]. All experiments were carried out twice in tripli-
cate, amplification plots were analyzed using the ABI
Prism 7700 SDS version 1.7 software. Expression levels of
mRNA were quantified by the relative standard curve
method, according to the User Bulletin #2 for ABI Prism
7700 SDS. Briefly, the target amount was divided by the
endogenous reference (GAPDH) amount to obtain a nor-
malized target value for each sample. The relative quantity
of cytokine mRNA levels was calculated by dividing each
of the normalized target values by the normalized calibra-
tor value for each sample, and was expressed as n-fold dif-
ference and mean ± SD. CNS samples from control rabbits
treated with PBS(-) were used as calibrators in this study.Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
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Statistics
Mean ± SEM or mean ± SD were determined, and to com-
pare mean values in 2 separate groups, Student's t-test was
used. Values of P < 0.05 were considered to be significant.
Results
Clinical findings and laboratory studies
In all rabbits injected with 0.1 to 4.0 μg/kg of Stx2, diges-
tive symptoms such as anorexia, weight loss, and diarrhea
were observed (Table 1). The 50% lethal dose was 0.79
μg/kg, and neurological symptoms developed in 2 of 4
rabbits (50%) injected with 1.0 μg/kg of Stx2 and in 5 of
6 (83.3%) treated with 2.0 to 4.0 μg/kg of toxin (Table 1).
As early as 28~42 h after injection, among the 23 animals
injected with 1.0 to 4.0 μg/kg (including the 16 in table
1), 18 showed neurological symptoms, which included
mild gait disturbance in 2 animals and paralysis in 16 rab-
bits. There were no significant changes in the hematolog-
ical and blood biochemical values at the onset of
neurological symptoms when compared with those
obtained before administration of the toxin (not shown),
except for a slight elevation in the leukocyte count (8345
± 394 and 9602 ± 755, before administration and at the
onset of neurological symptoms, respectively).
Gb3/CD77 expression and histopathological evaluation
Regional distribution and cellular localization of Gb3/CD77
Specific and intense fluorescence signals were strongly
detected on the blood vessels of the spinal cord gray mat-
ter (Fig. 1A). Whereas the intensity of fluorescence was
weaker in the white matter of the spinal cord (Fig. 1B),
root ganglia (not shown), and brain parenchyma (Fig.
1C). Signals were negative in the control sections incu-
bated with rat IgM isotype antibody (not shown). Double
staining with rhodamine-conjugated RCA 120, which rec-
ognizes and specifically binds to terminal [D-Galβ (1–4)-
D-GlcNAc] disaccharides [34], demonstrated different flu-
orescence signal patterns from Gb3/CD77 and revealed
colocalization of both in the small vessels and capillaries
(Fig. 1D to 1F); however, this was not evident in other
subsets of cells in the CNS parenchyma.
Spinal cord
The prominent pathological damage was massive necrotic
infarction in irregular form, which was mostly noted in
the gray matter of the cervical and lower thoracic to lum-
bar cords (Fig. 2A). In and around the ischemic lesions,
neuronal bodies were damaged and axons were swollen.
Small vessels and capillaries were frequently injured and
occluded by fibrin-like thrombi (Th in Fig. 2B) and some
exhibited eosinophilic exudates (dV) or microscopic hem-
orrhage (mH) as shown in Fig. 2B. In a rabbit with mild
ataxic gate but not paralysis, thrombi and/or microscopic
hemorrhage were only observed in the nerve roots. Some
axons were swollen and some of these were degenerated
or lost (Fig. 2C), neurons in the DRG exhibited normal
appearance (not shown).
Brain parenchyma
In contrast to the severe ischemic damages in the spinal
cord, a few foci of microscopic hemorrhage (Fig. 2D) and/
or ischemic lesions were scattered in the brain paren-
chyma and fibrin-like thrombi were often observed (Th)
in small vessels and capillaries at the onset of symptoms.
Neurons were damaged in the basal ganglia (Fig. 2E) and
thalamus at onset. These cells showed atrophy and darkly
stained cytoplasm. Several days after onset, at a later stage,
some neurons in CA1 of the rabbit hippocampus mor-
phologically exhibited an apoptotic appearance such as
condensed and fragmented nuclei in shrunken cytoplasm
(Fig. 2F).
Vascular damages
Elastica-Goldner staining showed that small vessels in the
infarction lesions in the spinal cord gray matter were
mainly damaged (Fig. 3A) and occluded by fibrin-like
thrombi (Th). Platelet thrombi (arrow in Fig. 3A) or frag-
mented red blood cells (arrow head in Fig. 3A) were also
present in a few vessels. Arterioles in the spinal cord
showed endothelium with pycnotic nuclei and swollen
cytoplasm as well as thickening of the vessel wall, but not
formation of thrombi (Fig. 3B). These vascular damages
were less severe in the brain parenchyma. Phosphotung-
stic acid hematoxylin (PTAH) staining revealed that most
of the thrombi in small vessels and exudates or precipi-
Table 1: Dosage range of Stx2 and clinical findings
Dose (μg/kg) neurological symptoms (%) Diarrhea/occult blood Body weight loss (%)
0.1 1a /5 (20) -~+/-~+ 8.0~38.8
0.25 0/4 (0) +/+ 13.2~25.6
0.5 0/4 (0) +/+ 22.0~36.7
1.0 2/4 (50) +/+ 26.7
2.0 5/6 (83.3) +/+ -b
4.0 5/6 (83.3) +/+ -b
aTransient gait disturbance was observed on the 4th to 6th day after administration of Stx2.
bnot measured.Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
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tates around capillaries were formed with fibrin in both
the spinal cord (Fig. 3C) and brain parenchyma.
Apoptotic cell death of neuronal cells and endothelial cells 
in the brain parenchyma
At the onset of paralysis, apoptotic granular neurons with
condensed brown DAB precipitate were observed in the
dentate gyrus of the hippocampus (Fig. 4A) and granular
layers of the cerebellum. TUNEL-positive neurons with
apoptotic bodies increased at a later stage several days
after onset in the pyramidal neurons in CA1 of the hip-
pocampus (Fig. 4B). Apoptotic changes were also
observed diffusely in neurons in other cerebral regions,
namely, the basal ganglia, thalamus and cerebral cortex
(Fig. 4C), among glial cells in the pons (Fig. 4D), and in
some endothelial cells of the small vessels and capillaries
in the cerebrum (Fig. 4E). TUNEL assay with omission of
TdT (Fig. 4F) was negative in all the regions. The number
of apoptotic cells per 10 fields (Fig. 4G) and of TUNEL-
positive vessels per 100 fields (Fig. 4H) at onset or at a
later stage were compared with those of control rabbits
treated with PBS(-). In the hippocampus, apoptotic neu-
rons were significantly elevated at both onset (53.1 ±
3.49) and a later stage (94.0 ± 7.65), (P < 0.01). Apoptotic
cells in the granular layers of the cerebellum (75.9 ± 4.76,
P < 0.05), other cerebral regions, including the basal gan-
glia, thalamus and cerebral cortex (74.1 ± 4.04, P < 0.01),
and TUNEL-positive vessels (88.2 ± 23.74, P < 0.05) were
significantly increased at a later stage.
Inflammatory responses in CNS
Microglial activation
At the onset of paralysis, intense GSL I-B4 staining of
microglial cells were diffusely observed in both the spinal
cord and brain. Microglial activation was obvious due to
the morphological change in the cells. Activated microglia
were markedly found in and around ischemic lesions in
the spinal cord (Fig. 5A) and extensively increased in the
brain parenchyma (Fig. 5B). A large number of microglia
exhibited an ameboid form when compared with the ram-
Immunofluorescence analysis of the localization of Stx receptor Gb3/CD77 in the rabbit CNS Figure 1
Immunofluorescence analysis of the localization of Stx receptor Gb3/CD77 in the rabbit CNS. Intense fluores-
cence was detected on the blood vessels of the spinal cord gray matter (A), whereas fluorescent signals were much weaker on 
those of the spinal cord white matter except anterior spinal artery (arrow) (B) and hippocampus (C). Confocal images of dou-
ble staining with rhodamine conjugated RCA 120 showed the different fluorescence signal patterns from Gb3/CD77 and 
revealed the colocalization of both in the small vessels and capillaries; Gb3/CD77 (D), RCA 120 (E), and merged (F). (Original 
magnification: (A)-(C) 200×; (A)-(E) 630×)
 Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
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ified form in the control sections of the spinal cord and
brain parenchyma (Fig. 5C and 5D, respectively). Interest-
ingly, microglial activation greatly increased before the
onset of neurological symptoms, as early as 6 to 12 h after
Stx2 injection and was also observed at a later stage.
Up-regulation of pro-inflammatory cytokine mRNA
Since microglial activation was observed before onset, the
expression levels of pro-inflammatory cytokine mRNA
were examined 24 h after administration of 2.5 μg/kg Stx2
(n = 2) in the frontal area, basal ganglia, hippocampus,
thalamus, temporal cortex, midbrain, cerebellum, pons
and medulla, cervical, thoracic and lumbar spinal cord,
and compared to the expression levels in the same regions
of rabbits injected with PBS(-) as a calibrator (n = 2).
Expression levels of TNF-α (Fig. 6A) and IL-1β (Fig. 6B)
mRNA increased in all regions of the rabbits treated with
Stx2 although the neurological signs had not developed at
this time point. TNF-α transcripts were substantially up-
regulated (by 15.55 ± 1.66~128.53 ± 13.54 fold increase)
and particularly overexpressed in 4 regions of the cere-
brum, namely, the basal ganglia, hippocampus, thalamus,
and cerebral cortex (128.53 ± 13.54, 107.35 ± 10.05,
106.73 ± 8.35, 93.65 ± 3.76 fold, respectively); TNF-α
expression also greatly increased in the cerebellum (51.62
± 4.43 fold). Whereas the IL-1β mRNA levels were moder-
ately increased (by 2.63 ± 0.30~12.14 ± 0.68 fold), except
in the hippocampus (27.60 ± 1.71 fold). Comparable
results were obtained using different set of rabbits.
Discussion
The present study demonstrated that in the brain of rab-
bits treated with purified Stx2, neurodegenerative events
coincide with inflammatory responses characterized by
microglial activation and production of pro-inflamma-
tory cytokines. In addition, these events greatly differed
Neuropathology in the rabbits treated with 2.5 μg/kg Stx2 (H&E staining) Figure 2
Neuropathology in the rabbits treated with 2.5 μg/kg Stx2 (H&E staining). (A) The lower segment of the lumbar 
spinal cord showed extensive necrotic infarction in the gray matter at the onset of severe paraplegia. (B) Higher magnification 
of ischemic lesions in the panel (A), small vessels with fibrin-like thrombi (Th), degenerated vessels (dV), and microscopic hem-
orrhage (mH) were observed. (C) Nerve roots of the rabbit with ataxic gate showed microvascular thrombi and microscopic 
hemorrhage. Some nerve fibers were swollen and/or degenerated. In contrast to the spinal cord, (D) microscopic hemorrhage 
(arrows) were scattered in the brain parenchyma. At a later stage, neurons in the basal ganglia showed atrophy, darkly stained 
cytoplasm (E), and in the hippocampus some pyramidal neurons morphologically showed apoptotic changes with shrunken 
cytoplasm and apoptotic bodies (arrows) (F). (Original magnification: (A) 5.2×; (B) 250×, (C) and (D) 100×, (E) and (F) 
400×.)
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Vascular degeneration in the rabbits treated with 2.5 μg/kg Stx2 Figure 3
Vascular degeneration in the rabbits treated with 2.5 μg/kg Stx2. (A) In the infarction lesions in spinal cord gray mat-
ter, small vessels were damaged with extravascular exudates and occluded with fibrin-like (Th) and platelet (arrow) thrombi 
and with fragmented erythrocytes (arrow head). Some arteries and arterioles (B) in the spinal cord showed an endothelium 
with pycnotic nuclei and swollen cytoplasm as well as thickening of the vessel walls. (C) PTAH staining indicated that most of 
the thrombi and exudates or precipitates around the capillaries were formed with fibrin in both the spinal cord and brain 
parenchyma. (A) &(B): Elastica-Goldner staining. (Original magnification: 400×)
 Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
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TUNEL assay of brain sections from rabbits treated with 2.5 μg/kg of Stx2 Figure 4
TUNEL assay of brain sections from rabbits treated with 2.5 μg/kg of Stx2. (A) Condensed dark brown cells were 
detected in the dentate gyrus of the hippocampus at the onset of paralysis. TUNEL-positive neurons showing shrunken cyto-
plasm, pycnotic nuclei, and/or apoptotic bodies increased at a later stage in the following other regions: CA1 of the hippocam-
pus (B) and cerebral cortex (C). Apoptotic glial cells in pons (D) and small vessels (E) with condensed cytoplasm and 
apoptotic bodies were also observed at a later stage. (F) TUNEL assay without TdT showed no positive staining. (G) Quanti-
tative evaluation of TUNEL-positive cells per 10 fields in the hippocampus, cerebellum, and other cerebral regions, including 
the basal ganglia, thalamus, and cerebral cortex, and (H) TUNEL-positive vessels per 100 fields in the cerebral parenchyma at 
the onset of neurological symptoms and at a later stage when compared with control rabbits treated with PBS(-) (n = 2 in each 
group). The number of apoptotic cells significantly increased in the hippocampus at both onset and a later stage, and in granular 
layers of the cerebellum and other cerebral regions at a late stage. TUNEL-positive vessels were significantly elevated at a later 
stage. *: P < 0.01 and **: P < 0.05. (Original magnification: (A) and (F) 200×, (B) 800×, (C) and (E) 600×, (D) 400×)
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from those in the spinal cord although the primary action
of Stxs was cytotoxicity against vascular endothelial cells
expressing Gb3/CD77, not against neuronal cells, in both
the spinal cord and brain.
Early studies showed that neuropathology, such as
endothelial injury with thrombi and ischemic damage in
rabbits treated with Stx1 or Stx2, was severe and extensive
in the spinal cord but minimal in the brain [4,6]; this indi-
cated specific binding of Stx1 to the endothelial cells of
capillaries and vascular damage in the affected rabbit tis-
sue [4]. These are in accordance with our results that neu-
ropathological damage is markedly associated with
regional distribution and cellular localization of Gb3/
CD77 expression in the CNS parenchyma, indicating that
the cytotoxic effects of Stx2 on endothelial cells was pro-
portionate to the extent of Gb3/CD77 expression. Subse-
quent progression of acute neuronal injury in the spinal
cord gray matter is mainly responsible for the paralysis
that is the prominent clinical manifestation in the rabbit
model treated with toxins.
Unlike the severe and massive ischemic insults in the spi-
nal cord, the remarkable histopathology observed in the
brain was due to neuronal cell death as evaluated by the
TUNEL assay. Neuronal apoptosis was observed in both
the dentate gyrus of the hippocampus and granular layers
of the cerebellum at the onset of neurological symptoms,
thereafter, significantly increased at a later stage several
days after onset in more cell subsets, such as the pyrami-
dal neurons in the hippocampus, neurons in other
regions, and glial cells in the white matter as well as in vas-
cular endothelial cells in the cerebral parenchyma. Toxin
binding was detected in ependymal cells and the myelin
sheath as well as the endothelial cells in brain lesions of
the rabbit injected with Stx2 [7], but not in the neurons
[4,7]. Neuronal changes in a baboon exposed to a high
level of Stx1 [35] and in a rabbit treated with Stx2 [36]
were microscopically demonstrated. Further, Stx2 admin-
istered into the cerebroventricular space was detected in
astrocyte and neuronal fibers in the rat corpus striatum,
resulting in their ultrastructural alterations [37]. However,
the mechanism by which toxin binding leads to neuronal
damages has not been elucidated. Besides the brain
endothelial cells, GB3/CD77 expression was not detected
in either neurons or glial cells by the IFA. This suggests
that Stxs might not directly exhibit essential cytotoxic
action, i.e., protein synthesis inhibition, against neuronal
cells. Accordingly, neuronal degeneration following Stx2
administration is very likely caused by indirect effects,
rather than by direct cytotoxicity of the toxin against neu-
ronal cells.
In the current study, immunoreactivity and morphologi-
cal changes of microglia were increased as early as 12 h
after Stx2 injection and TNF-α transcripts were markedly
increased in the brain before onset of neurological symp-
toms. Most pathological changes in the CNS are accompa-
nied by an involvement of glial cells, particularly
microglia, which are activated at an early stage and change
their morphology rapidly in response to even minor path-
ological conditions in the CNS [15,38]. We previously
observed widespread activation of microglia in the brain
parenchyma in acute fatal measles cases in which only
endothelial cells of small vessels were infected with the
measles virus [39]. This suggests that endothelial injury by
Stx2 can also evoke microglial activation. Endogenous
thrombin generated by vascular damage might contribute
to activation of microglia [40]. Activated microglia, by
inhibiting both the basal formation of new neurons and
increased neurogenesis in response to brain insults, may
contribute to the neurodegenerative processes [41]. Fur-
thermore, activated microglia are known to produce pro-
inflammatory cytokines, such as TNF-α and IL-1β
[15,23,38,40], which are observed long before significant
neuronal death at the early phases of neuroinflammatory
events [16]. TNF-α is shown to induce neurodegeneration
directly, through signaling death pathway of TNF-α/p55
TNF receptor-1 in neurons [24,42] and oligodendrocytes
[25] or through inducing activation of caspase-3 in a
mixed neuro-glial culture system [43], furthermore, indi-
rectly, through inhibiting receptor signaling for neuronal
survival via the protective peptide insulin-like growth fac-
GSL I-B4 isolectin staining for microglia Figure 5
GSL I-B4 isolectin staining for microglia. In the rabbits 
treated with 2.5 μg/kg of Stx2, a large number of microglia 
exhibited an ameboid form in and around the ischemic 
lesions in the lumbar cord gray matter (A) and extensively 
increased in the brain parenchyma, thalamus (B) at the onset 
of paralysis, when compared with the lumbar cord (C) and 
thalamus (D) of control rabbits injected with PBS(-), showing 
a ramified form of microglia. (Original magnification: 800×)
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tor I [44] or through inducing microglial glutamate
release in an autocrine manner [45]. Collectively, our
observations that inflammatory responses, such as micro-
glial activation and TNF-α overexpression, occurred in the
brain of the rabbits at an early stage suggest that neuronal
apoptosis and degeneration is probably triggered by neu-
roinflammation that is induced in response to primary
endothelial injury by Stx2. The synergistic effects of TNF-
α and IL-1β, however, have been demonstrated in human
fetal brain cell cultures [42], thus suggesting that IL-1β,
which showed a small increase in our animal model,
might also participate in the neurodegenerative processes.
Previous studies have demonstrated that Stx1 induces
apoptosis in the brain microvascular endothelial cells [46]
in a dose- and time-dependent manner [11,47]. Toxins
inhibit the expression of the anti-apoptotic Bcl-2 family
member Mcl-1 in endothelial cells [12], and caspase
inhibitors block apoptotic cell death [11,46,47]. Gb3/
CD77 expression on the membrane of these cells is
required to activate the death signal cascade and enhance
Bax expression [11]. Therefore, in contrast to neuronal cell
death, endothelial apoptosis in the brain parenchyma is
most likely Gb3/CD77-dependent and induced by the
direct cytotoxic effects of Stx2. Moreover, in vitro studies
have shown that pro-inflammatory cytokines such as
TNF-α and IL-1β markedly increased the Gb3/CD77 con-
tent of and Stx-binding to brain microvascular endothelial
cells, resulting in the up-regulation of cytotoxicity [48-50]
and apoptotic cell death [46].
There are no specific therapies to ameliorate the course of
neurological involvement during STEC infection. How-
ever, treatment with nafamostat mesilate (6-amidino-2-
naphthyl p-guanidinobenzoate dimethanesulfonate) sig-
nificantly decreased the pro-inflammatory cytokine levels
in the brain and changed the neuropathology in gnotobi-
otic mice infected with STEC O157:H7 [26]. Inhibition of
Real-time quantitative PCR study Figure 6
Real-time quantitative PCR study. TNF-α (A) and IL-1β (B) transcripts in 12 regions of the rabbit CNS at 24 h after 
injection of PBS(-) as a calibrator (open bar: 1 ± SD) or 2.5 μg/kg Stx2 (closed bar: mean ± SD). All data were normalized to 
the internal reference GAPDH amounts and expressed as an n-fold increase relative to normalized calibrator values in each 
region. Both TNF-α and IL-1β mRNA levels were greatly up-regulated. In particular, TNF-α transcripts were significantly over-
expressed in the cerebrum, basal ganglia, hippocampus, thalamus, and cerebral cortex. *: P < 0.01 compared to frontal region.Journal of Neuroinflammation 2008, 5:11 http://www.jneuroinflammation.com/content/5/1/11
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Stx1-induced TNF-α production with anisodamine (race-
anisodamine hydrochloride) prolonged the survival time
and decreased the lethality of mice injected with the toxin
[51]. Suppressing neuroinflammatory responses generally
[26,52] or neurotoxic molecules selectively [19,21,45] has
recently been recognized as an effective therapeutic strat-
egy for neurodegenerative diseases. Therefore, anti-
inflammatory compounds or selective inhibitors may
have therapeutic potential for Stx-induced neurological
manifestation as well.
Conclusion
The Stx receptor Gb3/CD77 was expressed on endothelial
cells in the brain parenchyma, but not on neurons or glial
cells. Therefore, vascular damages and induction of
endothelial apoptosis were very likely caused by direct
cytotoxic action of Stx2. Apoptotic cell death of neurons
and/or glial cells, however, may result from inflammatory
responses in CNS following primary endothelial injury by
Stx2; this is because microglial activation and significant
up-regulation of TNF-α and IL-1β transcripts occurs in the
brain parenchyma of rabbits treated with Stx2. Collec-
tively, these results suggest that inflammatory responses
play a critical role in progression of neurological impair-
ment during STEC infection; however, the expression of
Gb3/CD77 in the human CNS still remains unclear.
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